Key result
SGLT2 inhibitors consistently reduce HF hospitalizations and slow CKD progression, even without diabetes.
Why the study?
While SGLT2 inhibitors consistently reduce heart failure hospitalizations and chronic kidney disease progression, their effects on major adverse cardiovascular events and other outcomes remain variable and incompletely defined.
SGLT2 inhibitors have evolved from diabetes medications to foundational, guideline-directed therapies for heart failure across all ejection fractions and chronic kidney disease.
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors warrant priority for HF hospitalization and CKD; leaves open consistent MACE reduction.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially developed as antihyperglycemic agents for type 2 diabetes mellitus but have become foundational therapies in cardiovascular and cardiorenal medicine. Randomized trials and meta-analyses show their most consistent benefits are reducing heart failure hospitalization and slowing chronic kidney disease progression, including in patients without diabetes. In contrast, their effects on major adverse cardiovascular events, myocardial infarction, stroke, arrhythmias, and postmyocardial infarction outcomes remain more variable and incompletely defined. Mechanistically, SGLT2 inhibitors act through natriuresis, osmotic diuresis, plasma-volume redistribution, improved renal hemodynamics, reduced ventricular loading, attenuation of inflammation and fibrosis, and possible improvements in myocardial energetics and vascular biology. In heart failure, they are now central to guideline-directed medical therapy across reduced, mildly reduced, and preserved ejection fraction phenotypes, with increasing support for early in-hospital initiation in selected patients. In chronic kidney disease, they link renal protection with meaningful cardiovascular benefit, particularly for heart failure outcomes. This review summarizes their pharmacology, mechanisms, cardiovascular evidence, safety, implementation challenges, and future directions in precision cardiorenal therapy.
No takes yet. Share an insight, caveat, or question.
Neshat et al. (2026) conducted a review in Cardiovascular and cardiorenal disease. SGLT2 inhibitors was evaluated. SGLT2 inhibitors consistently reduce heart failure hospitalization and slow chronic kidney disease progression, including in patients without diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: